Targovax (CRNA.OL) Stock Analysis & AI Equity Report
Targovax (CRNA.OL) overview
Targovax (CRNA.OL) stock analysis and AI equity research. For the latest completed financial year, 2022, Targovax reported revenue of NOK 10.0m and operating profit of NOK -494m; the year-end share price was 1.10 NOK and market capitalisation was NOK 207m. Targovax is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Targovax's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-12-12. Data will be refreshed during report generation.
About Targovax
Targovax ASA is a biotechnology company developing circular RNA and immunotherapy medicines for cancer. Its programs include a proprietary circRNA platform and earlier-stage oncology assets such as ONCOS-102 and mutant RAS cancer vaccine candidates. The company is in a strategic transition toward circRNA-based therapeutics while continuing to advance selected immunotherapy programs.
Generate the Targovax report
Targovax is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Targovax and represent the latest completed financial year (2022). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.